Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)
Diabetes Research and Clinical Practice Sep 27, 2021
Hashimoto-Kameda R, Cho KY, Nomoto H, et al. - According to this randomized, open-label, parallel-group trial, switching from dipeptidyl peptidase-4 inhibitor (DPP-4i) to luseogliflozin reduced nighttime systolic BP (SBP) and pulse rate (PR); also, blood pressure (BP) circadian rhythm was improved.
Patients on DPP-4i were either switched to luseogliflozin 2.5 mg/day (Luseo group; n = 30) or kept on DPP-4i (DPP-4i group; n = 26) in the trial.
Nighttime and daytime SBP were considerably lower in the Luseo group compared with the DPP-4i group.
Similarly, the Luseo group experienced a significant decrease in nighttime PR.
In the Luseo group, the proportion of patients with abnormal BP circadian rhythms (non-dipper pattern plus riser pattern) was significantly lower.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
